BCMA – Medxy AI

CT0590: A Triple-Knockout Allogeneic BCMA CAR T Therapy Advances Treatment in Multiple Myeloma and Plasma Cell Leukemia

By MedXY 09/10/2026

CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rejection challenges.

$Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease$

Hematology-Oncology news Oncology

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease

By MedXY 08/20/2026

Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.

$Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma$

Hematology-Oncology news Oncology

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

By MedXY 07/13/2026

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended dose.

Hematology-Oncology news

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY 03/13/2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Hematology-Oncology news

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

By MedXY 12/08/2025

Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and short follow-up.

Hematology-Oncology news Oncology

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma

By MedXY 11/17/2025

Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 trials in relapsed/refractory multiple myeloma.

$Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach$

Hematology-Oncology news Rheumatology

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY 11/12/2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and plasma‑cell clones.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results$

Hematology-Oncology news

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

By MedXY 11/04/2025

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in relapsed/refractory multiple myeloma.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

$Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety$

Hematology-Oncology news Specialties

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety

By MedXY 09/21/2025

Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.